GlassScriptPhysician profile
Shih-Ting Chiu
NPI 1164758108
$9,703.31
in general payments reported to CMS, 2019-2025
26 companies · $46.35 in 2025
The $46.35 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,996 · 2022: $2,841 · 2023: $4,041 · 2024: $780 · 2025: $46.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,469 · Consulting Fee: $1,166 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,469.30 |
| Consulting Fee | $1,165.50 |
| Education | $232.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,064.53 | 2021-2023 | Dupixent |
| Abbvie INC. | $1,589.63 | 2021-2024 | |
| Genzyme Corporation | $794.14 | 2021-2024 | |
| Leo Pharma INC. | $711.74 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $705.95 | 2021-2024 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $677.04 | 2021-2023 | Opzelura, Jakafi |
| Pfizer INC. | $545.99 | 2021-2023 | |
| Journey Medical Corporation | $406.19 | 2022-2023 | |
| Dermavant Sciences, INC. | $324.47 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $261.41 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $256.80 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $223.36 | 2021-2023 | Winlevi, Absorica Ld |
| Vyne Pharmaceuticals INC. | $156.93 | 2021 | |
| Allergan, INC. | $155.70 | 2022 | |
| Epi Health, LLC | $131.64 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.35 | 2021-2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $94.54 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $91.34 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $88.18 | 2022-2023 | |
| Genentech USA, INC. | $73.89 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $62.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.74 | 2021 | |
| Strata Skin Sciences, INC. | $46.02 | 2023 | Xtrac |
| Almirall LLC | $23.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.87 | 2022 | |
| Dermira, INC. | $17.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shih-Ting Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.